As of 2025, I've got over 10 years of researching companies. In total, throughout my investing life, I estimate that I researched (in depth) well over 1000 companies, from commodities like oil, natural gas, gold and copper to tech like Google or Nokia and many emerging market stocks, which I believe could help me provide useful content for readers. After writing my own blog for about 3 years, I decided to switch to a value investing-focused YouTube channel, where I researched hundreds of different companies ...

Montreal, Quebec--(Newsfile Corp. - November 21, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), announces that the holders of the Corporation's 8% convertible debentures issued on November 16, 2024 (the "Debentures") have converted all of the principal amount and the accrued interests thereof into an aggregate number of 2,607,600 common shares of the Company (eac ...

If you want full access to all our reports, data and investing ideas, join The Aerospace Forum , the #1 aerospace, defense and airline investment research service on Seeking Alpha, with access to evoX Data Analytics, our in-house developed data analytics platform.Leonardo DRS, Inc. (NYSE: DRS ) has fallen 22.3% since I downgraded the stock from Buy to Hold , significantly underperforming the S&P 500’s ( SP500 ) 14.1% gain. The pullback reflects not only company-specific sentiment but alsoDhierin-Perkash Bec ...

Core Insights - H.C. Wainwright upgraded Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to a "Buy" rating and increased its price target from $568 to $620, reflecting confidence in the company's future performance [1][5] - The current stock price of MDGL is $559.40, showing a 3.19% increase, indicating strong investor interest and market activity [3][5] - Madrigal's market capitalization is approximately $12.41 billion, highlighting its significant presence in the biopharmaceutical sector [4] Company Developments - Madrigal Pharmaceuticals granted equity awards to new non-executive employees as part of its 2025 Inducement Plan, which includes 2,125 restricted stock units designed to attract talent and ensure employee retention [2][5] - The stock has fluctuated between $535 and $563.50 today, with a yearly high of $577.90 and a low of $265, reflecting its volatility and growth potential [3]

Among investors with a primary focus on growth or income, there probably isn't a more polarizing ETF than YieldMax Ultra Option Income Strategy ETF ( ULTY ). With the recent announcement that it is going to implement a 10-for-1 reverseI am a former investment advisor and owner of several businesses. These days I invest only for myself while continuing to write on a variety of financial and economic topics.Analyst’s Disclosure:I/we have a beneficial long position in the shares of ULTY either through stock ow ...

Ernest HoffmanErnest Hoffman is a Crypto and Market Reporter for Kitco News. He has over 15 years of experience as a writer, editor, broadcaster and producer for media, educational and cultural organizations. Ernest began working in market news in 2007, establishing the broadcast division of CEP News in Montreal, Canada, where he developed the fastest web-based audio news service in the world and produced economic news videos in partnership with MSN and the TMX. He has a Bachelor's degree Specialization in ...

What does the September jobs report, delayed by six weeks because of the government shutdown, say about the economy? Lydia DePillis, our economics reporter, describes how the report, which was better than expected, comes at a moment of deep uncertainty. ...

Core Insights - AECOM is focused on continuous improvement to establish itself as an industry leader in infrastructure [2] Group 1 - The company has been working for the past two years to enhance its position in the market [2] - AECOM's leadership team, including the CEO, President, and CFO, is actively engaged in driving the company's strategic initiatives [1] - The emphasis on continuous improvement has been a guiding principle for the organization over the last six years [2]

I analyze oil and gas companies and related companies like Archrock in my service, Oil & Gas Value Research, where I look for undervalued names in the oil and gas space. I break down everything you need to know about these companies -- the balance sheet, competitive position and development prospects. This article is an example of what I do. But for Oil & Gas Value Research members, they get it first and they get analysis on some companies that is not published on the free site. Interested? Sign up here for ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased CarMax, Inc. securities between June 20, 2025, and November 5, 2025, about the January 2, 2026, deadline to become a lead plaintiff in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased CarMax securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 2, 2026 [3]. - The lawsuit alleges that CarMax's defendants made materially false and misleading statements regarding the company's growth prospects, which were overstated due to temporary market conditions [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action litigation [4].